

Edgar Filing: ENCYSIVE PHARMACEUTICALS INC - Form SC TO-T/A

ENCYSIVE PHARMACEUTICALS INC
Form SC TO-T/A
April 08, 2008

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE TO/A

Tender Offer Statement under Section 14(d)(1) or 13(e)(1)
of the Securities Exchange Act of 1934

(Amendment No. 4)

ENCYSIVE PHARMACEUTICALS INC.
(Name of Subject Company (Issuer))

EXPLORER ACQUISITION CORP.
(Offeror)

a wholly-owned subsidiary of

PFIZER INC.
(Parent of Offeror)

(Names of Filing Persons (identifying status as offeror,
issuer or other person))

COMMON STOCK, \$0.005 PAR VALUE
(Title of Class of Securities)

29256X107
(CUSIP Number of Class of Securities)

MARGARET M. FORAN, ESQ.
PFIZER INC.
235 EAST 42ND STREET
NEW YORK, NY 10017
PHONE (212) 573-2323
(Name, address, and telephone numbers of person
authorized to receive notices and
communications on behalf of filing persons)

Copies to:
RAYMOND O. GIETZ, ESQ.
WEIL, GOTSHAL & MANGES LLP
767 FIFTH AVENUE
NEW YORK, NY 10153
(212) 310-8000

CALCULATION OF FILING FEE

TRANSACTION VALUATION(1)	AMOUNT OF FILING FEE(2)
\$210,165,550	\$8,260

Edgar Filing: ENCYSIVE PHARMACEUTICALS INC - Form SC TO-T/A

interest thereon and less any required withholding taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase dated March 4, 2008 (the "Offer to Purchase") and in the related Letter of Transmittal (which, together with any amendments or supplements to the Offer to Purchase and the Letter of Transmittal, collectively constitute the "Offer"). Copies of the Offer to Purchase and the Letter of Transmittal were filed as Exhibits (a)(1)(A) and (a)(1)(B) to the Schedule TO, respectively. The Offer is made pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 20, 2008, by and among Encysive, the Purchaser and Pfizer.

All capitalized terms used in this Amendment No. 4 and not otherwise defined herein shall have the meanings ascribed to them in the Schedule TO or the Offer to Purchase.

The information in the Offer to Purchase and the related Letter of Transmittal is incorporated into this Amendment No. 4 by reference to all of the applicable items in the Schedule TO, except that such information is amended and supplemented to the extent specifically provided in this Amendment No. 4.

ITEM 11. ADDITIONAL INFORMATION.

Item 11 of the Schedule TO is amended and supplemented by adding the following text to such Item:

"On April 8, 2008, Pfizer issued a press release announcing an extension of the subsequent offering period of the Offer to 5:00 p.m., New York City time, on April 14, 2008. The subsequent offering period had been previously scheduled to expire at 5:00 p.m., New York City time, on April 7, 2008. According to the Depositary, a total of 67,435,726 Shares (representing approximately 83.3% of the outstanding Shares), had been tendered prior to such time."

ITEM 12. EXHIBITS.

Item 12 of the Schedule TO is hereby amended and supplemented to include the following:

"(a) (5) (H) Press Release issued by Pfizer on April 8, 2008."

SIGNATURES

After due inquiry and to the best of the knowledge and belief of each of the undersigned, each of the undersigned hereby certifies that the information set forth in this statement is true, complete and correct.

Date: April 8, 2008

PFIZER INC.

By: /s/ David Reid

Name: David Reid
Title: Assistant Secretary

EXPLORER ACQUISITION CORP.

By: /s/ Lawrence Miller

Name: Lawrence Miller
Title: Vice President